antibiotics

In 2023, one in six laboratory-confirmed bacterial infections were found to be resistant to antimicrobials, according to a report published by the World Health Organisation (WHO). Between 2018 and 2023, resistance increased in more than 40% of monitored antibiotics, which ‘is limiting empirical treatment options and driving a shift from oral to intravenous treatments, including greater reliance on second-line and last-resort antibiotics,’ the report warns. For example, globally, nearly 45% of Escherichia coli bacteria are resistant to third-generation cephalosporins, a proportion that varies from 20% in Europe to more than 70% in Africa.

Gonorrhoea is the second most common sexually transmitted disease in the world, with 80 million cases each year. There is no effective vaccine, and the bacteria responsible are becoming resistant to common antibiotics. Some studies have suggested that the meningococcal B vaccine, a unrelated bacterium, may offer partial protection against gonorrhoea. Now, an Italian team has identified 17 antibodies that could explain this cross-immunity, which, according to the authors, could be used to develop treatments and vaccines. The results are published in the journal Science Translational Medicine.

A team from Canada and the United States has found a candidate to form part of a new class of antibiotics, lariocidin. This could be effective against multi-resistant bacteria. The finding is published in the journal Nature.

Antimicrobial resistance caused around 5 million deaths worldwide in 2019. The use of vaccines has the potential to reduce these deaths - 515,000 fewer deaths per year - according to a report published by the WHO. The work focused on 24 pathogens and 44 vaccines, licensed by regulatory agencies, in clinical development or in development. By counting existing vaccines alone, antibiotic use could be reduced by 142 million daily doses per year.  

Cresomycin, a new synthetic molecule, exhibits robust efficacy against multiple evolutionarily divergent forms of antimicrobial resistance (AMR), according to a study published today in Science. By structurally analyzing how antibiotics bind to ribosomes of various bacterial species, researchers developed a new antibiotic molecule that adopts the exact conformation necessary for ribosomal binding.

The risk of developing resistant bacteria is higher in some people, such as those who have to take long-term antibiotics after organ transplantation. To try to reduce them, a phase 1 clinical trial has performed a fecal transplant on 10 people who had previously received a kidney transplant and had resistant bacteria. The fecal transplants accelerated decolonization, shortened the time it took to test negative for multidrug-resistant organisms, and, according to the authors, may also "reduce the recurrence of infections." The results are published in the journal Science Translational Medicine.

A research team including scientists from the University of Santiago de Compostela and the Centro Tecnológico Agroalimentario de Lugo has analysed the presence of potentially pathogenic bacteria in 100 meat samples bought in supermarkets in Oviedo, Spain in 2020. The researchers found E. coli bacteria which produce enzymes that make the bacteria resistant to various types of antibiotics in more than half of the turkey (68 %) and chicken (56 %) samples, and less frequently in beef (16 %) and pork (12 %) samples. They also found E. coli bacteria that can cause urinary tract infections. The team presented these results at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which is being held in Copenhagen, Denmark, until 18 April. 

Research concludes that different types of antidepressants are capable of generating resistance to multiple antibiotics, even when administered for short periods of time. The results are published in the journal PNAS.

The World Health Organisation (WHO) has published a report with data reported by 87 countries in 2020 warning of increasing antibiotic resistance in bacterial infections in humans. The report shows resistance levels of more than 50 % in bacteria that frequently cause bloodstream infections in hospitals, such as Klebsiella pneumoniae and Acinetobacter spp. 

The EMA's annual European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) report shows that sales of antibiotics for animal use have decreased by 47% between 2011 and 2021. In addition, sales of antibiotics considered "critically important" for use in humans have also decreased.